Trial Profile

Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Relatlimab (Primary)
Indications Soft tissue sarcoma
Focus Proof of concept; Therapeutic Use
Acronyms CONGRATS

Most Recent Events

21 Feb 2023 Planned End Date changed from 1 Feb 2025 to 1 Dec 2025.
21 Feb 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jun 2024.
13 Sep 2022 Trial design presented at the 47th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com